Comparison of Ziv-aflibercept and Ranibizumab for Macular Edema Secondary to Central Retinal Vein Occlusion

Comparison of Ziv-aflibercept with Ranibizumab in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202609559057862

Enrollment

Registered

2026-09-07

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Intravitreal Ziv aflibercept

Intravitreal Ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ischemic or non-ischemic central retinal vein occlusion (CRVO) with associated macular edema. CRVO diagnosis and perfusion status were confirmed by fundus fluorescein angiography (FFA). Central macular thickness (CMT) was at least 400 µm as documented by spectral-domain optical coherence tomography (SD-OCT).

Exclusion criteria

Exclusion criteria: Previous intravitreal anti-VEGF therapy or intravitreal triamcinolone in the study eye within the preceding 3 months; coexisting retinal pathology that could affect visual acuity or central macular thickness, including diabetic retinopathy, age-related macular degeneration, or chorioretinitis; dense media opacity precluding adequate FFA or OCT imaging; or inability to complete the scheduled follow-up visits.

Design outcomes

Primary

Measure	Time frame
Change in best-corrected visual acuity (BCVA), measured in logMAR, from baseline during follow-up.;Change in central macular thickness (CMT), measured in micrometers by spectral-domain optical coherence tomography (SD-OCT), from baseline during follow-up.	—

Secondary

Measure	Time frame
Change in intraocular pressure (IOP), measured in mmHg, from baseline during follow-up.;Occurrence of ocular, systemic, and injection-related adverse events during the study follow-up period.;Number of additional intravitreal injections required after completion of the three loading doses.;Simplified cost-effectiveness comparison based on drug-acquisition cost, including estimated cost per patient dose and cost in relation to visual and anatomical improvement.	—

Measure

Time frame

Change in intraocular pressure (IOP), measured in mmHg, from baseline during follow-up.;Occurrence of ocular, systemic, and injection-related adverse events during the study follow-up period.;Number of additional intravitreal injections required after completion of the three loading doses.;Simplified cost-effectiveness comparison based on drug-acquisition cost, including estimated cost per patient dose and cost in relation to visual and anatomical improvement.

—

Countries

Egypt

Contacts

Public ContactAhmed Saber

Department of Ophthalmology Faculty of Medicine Zagazig University

ahmedasaber62@gmail.com+201211748035

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026